Granza Bio

Executive Summary

Granza Bio is a pioneering UK-based biotechnology company founded in 2020 that is developing a novel drug delivery platform inspired by cytotoxic immune cells. The company's core technology, termed 'attack particles,' are autonomous killing entities naturally released by immune cells. By isolating and reprogramming these particles, Granza aims to create targeted therapeutics for cancer, autoimmune diseases, and infectious diseases. This approach offers potential advantages in specificity, potency, and reduced off-target effects compared to conventional drug delivery systems. As a privately held early-stage venture with no disclosed funding or valuation, Granza Bio represents an emerging player in the drug delivery space with a differentiated biological mechanism. The company's progress to date is limited by its early stage, with no publicly available pipeline or clinical data. However, the foundational science behind attack particles has attracted interest from academic collaborators and potential partners. Granza Bio's success will depend on securing funding for preclinical validation and establishing proof-of-concept in relevant disease models. The therapeutic potential across multiple high-need areas could position the company for significant upside if the platform is successfully translated. Key risks include the technical challenges of isolating and engineering attack particles, competition from other drug delivery modalities, and the need for substantial capital to advance development.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data40% success
• Q2 2027Series A Funding Round50% success
• Q3 2026Academic or Industry Partnership35% success